Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth.
Lifeng Yang,Abhinav Achreja,Tsz-Lun Yeung,Lingegowda S Mangala,Dahai Jiang,Cecil Han,Joelle Baddour,Juan C Marini,Joseph Ni,Ryuichi Nakahara,Stephen Wahlig,Lisa Chiba,Sun Hye Kim,Joshua Morse,Sunila Pradeep,Archana Sidalaghatta Nagaraja,Monika Haemmerle,Noh Kyunghee,Mathew Derichsweiler,Thomas Plackemeier,Imelda Mercado-Uribe,Gabriel Lopez-Berestein,Tyler Moss,Prahlad T Ram,Jinsong Liu,Xiongbin Lu,Samuel C Mok,Anil K Sood,Deepak Nagrath
DOI: https://doi.org/10.1016/j.cmet.2016.10.011
IF: 29
2016-01-01
Cell Metabolism
Abstract:Reactive stromal cells are an integral part of tumor microenvironment (TME) and interact with cancer cells to regulate their growth. Although targeting stromal cells could be a viable therapy to regulate the communication between TME and cancer cells, identification of stromal targets that make cancer cells vulnerable has remained challenging and elusive. Here, we identify a previously unrecognized mechanism whereby metabolism of reactive stromal cells is reprogrammed through an upregulated glutamine anabolic pathway. This dysfunctional stromal metabolism confers atypical metabolic flexibility and adaptive mechanisms in stromal cells, allowing them to harness carbon and nitrogen from noncanonical sources to synthesize glutamine in nutrient-deprived conditions existing in TME. Using an orthotopic mouse model for ovarian carcinoma, we find that co-targeting glutamine synthetase in stroma and glutaminase in cancer cells reduces tumor weight, nodules, and metastasis. We present a synthetic lethal approach to target tumor stroma and cancer cells simultaneously for desirable therapeutic outcomes.